Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to determine if the Angiotech central venous catheter (CVC) is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing bacterial catheter colonization. Other objectives of this study are to determine if the Angiotech CVC is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing catheter-related local infection, and catheter-related bloodstream infection. This study will also assess the safety of the Angiotech CVC.
Central venous catheters are widely used for hemodynamic monitoring and the administration of fluids, drugs, and nutrition. The most frequent life-threatening complication of central venous catheter use is septicemia. Normal cutaneous flora may invade the intracutaneous tract during or after catheter insertion. The colonizing bacteria subsequently disseminate along the catheter surface and ultimately seed into the blood stream.
In the United States, a total of 250,000 cases of central venous catheter-related infections are estimated annually. Costs per infection are estimated as high as US$56,000. It is clinically imperative that effective measures be found to decrease catheter infection rates while minimizing the risk of the development of microbial resistance.
Primary Objective: The primary objective of this study is to determine the non-inferiority of the Angiotech Central Venous Catheter (CVC) when compared to the ARROWgard Blue® CVC to prevent bacterial catheter colonization.
Secondary Objectives: The secondary objectives of this study are to determine the non-inferiority of the Angiotech CVC when compared to the ARROWgard Blue® CVC to prevent:
Safety Objectives: This study will assess the safety of the Angiotech CVC.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ARROWgard Blue® CVC | Active Comparator | 7-French x 20-cm, triple lumen, short-term CVC |
|
| Angiotech CVC | Experimental | A 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Central Venous Catheter | Device | 7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of catheter colonization | Primary Objective: The primary objective of this study was to determine the non-inferiority of the Angiotech Central Venous Catheter (CVC) when compared to the ARROWgard Blue® CVC to prevent bacterial catheter colonization. | Maximum of 28 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stephen Heard, MD | University of Mass. Medical School Department of Anesthesiology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cardio-Thoracic Surgeons, P.C. | Birmingham | Alabama | 35235 | United States | ||
| Pulmonary Consultant Group |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Orange |
| California |
| 92868 |
| United States |
| Pulmonary Center Sharp Memorial Hospital | San Diego | California | 92123 | United States |
| Kaiser Permanente Santa Teresa | San Jose | California | 95119 | United States |
| Denver Health Medical Center | Denver | Colorado | 80204 | United States |
| Christiana Care Research Institute | Newark | Delaware | 19713 | United States |
| Florida Research Network, LLC | Gainesville | Florida | 32605 | United States |
| Atlanta Institute for Medical Research Inc | Decatur | Georgia | 30030 | United States |
| Kerry Thibodeaux, M.D. | Opelousas | Louisiana | 70570 | United States |
| UMASS Medical School, Dept of Anesthesiology | Worcester | Massachusetts | 01655 | United States |
| Newark Beth Israel Hospital | Newark | New Jersey | 07112 | United States |
| Pulmonary and Critical Care Medicine | Cincinnati | Ohio | 45267 | United States |
| St Vincent Mercy Medical Center, Bldg 1 | Toledo | Ohio | 43608 | United States |
| Medical University of Ohio | Toledo | Ohio | 43614 | United States |
| Universty of Oklahoma HSC | Oklahoma City | Oklahoma | 73104 | United States |
| Drexel University College of Medicine | Philadelphia | Pennsylvania | 19102 | United States |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | United States |
| Rapid City Regional Hospital | Rapid City | South Dakota | 57701 | United States |
| University of Virginia, Department of Anesthesiology | Charlottesville | Virginia | 22908 | United States |
| Winchester Medical Center | Winchester | Virginia | 22601 | United States |
| Franciscan Health System Research Center | Tacoma | Washington | 98405 | United States |
| ID | Term |
|---|---|
| D001424 | Bacterial Infections |
| ID | Term |
|---|---|
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D062905 | Central Venous Catheters |
| ID | Term |
|---|---|
| D062666 | Vascular Access Devices |
| D057785 | Catheters |
| D004864 | Equipment and Supplies |
Not provided
Not provided